132428-17-2

Upstream product

• 24978-68-5 18-aminoabieta-8,11,13-triene 
• 36714-65-5 (chloro-3 propyl)-2 (fluoro-4 phenyl)-2 dimethyl-5,5 dioxanne-1,3 
• 1446-61-3 leelamine 

Downstream Products

• 143667-12-3 1-(4-Fluoro-phenyl)-4-[(7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-ylmethyl)-amino]-butan-1-ol 
• 143667-16-7 1-(4-Fluoro-phenyl)-4-[(7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-ylmethyl)-amino]-butan-1-one 
• 132427-62-4 1-(4-fluorophenyl)-4-((1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl)methylamino)-1-butanone 

Relevant academic research and scientific papers

Anti-inflammatory phospholipase-A2 inhibitors. II. Design, synthesis and structure-activity relationship

The design and synthesis of a novel series of phospholipase-A2 (PLA2) inhibitor with antiinflammatory activity was based on a systematic structure-activity relationship (SAR) analysis.

Antiinflammatory phospholipase-A2 inhibitors. I.

A novel series of dehydroabietylamine derivatives has been synthesized and shown to be inhibitors of phospholipase-A2 (PLA2). These compounds exhibit in vivo antiinflammatory activity in the rat carrageenan paw edema assay and support the concept of PLA2 inhibition as an approach to the discovery of novel antiinflammatories.